Biotech Values

[turtlepower]

BMY/Ipilimumab

As previously noted, I think the OS data for the three arms trump the PFS and RR data that you posted in bold-faced text.

Sure but it appears that the secondary endpoint results have opened up questions about how effective the drug is. If the first line trial shows marginal or no efficacy how likely are physicians to prescribe ipi for 2nd line? It appears amongst physicians 10 and 6 months is low enough to question the results.

http://drericwhitman.wordpress.com/